retatrutide approval status fda ema 2025 Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) Demand for Unapproved Weight-Loss Drug
Description
Available from: Costa M
Gong N, Xiao Q, Zhu B, et al
Results slow: As the effects of GLP-1 treatments plateau (on the weighing scale) people will potentially lose motivation and patience to continue the course
The glucagon component increases energy expenditure and shifts metabolism toward fat oxidation while sparing muscle tissue
